EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa

Ischa M S Hoornstra, Junxiong Zhao, Harmen Middelveld, Siyu Sun, Claudia Schönichen, Johan W M Heemskerk, Hendrik Stragier, René Heylen, Bas de Laat, Mark Roest

Blood Vessels, Thrombosis & Hemostasis · 2025-11 · 2 (4) · 100100

DOI: 10.1016/j.bvth.2025.100100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2025-11. Verfasst von Ischa M S Hoornstra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Studies, Synapse Research Institute, Maastricht, The Netherlands. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Scholarship Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with hemorrhage after treatment with direct oral anticoagulants (DOACs) are saved from hematoma expansion by administration of Andexanet alfa, a modified factor Xa analog. A recent clinical trial points to incidental prothrombotic effects after Andexanet alfa treatment. We investigated mechanisms explaining the thrombogenic side effect. Calibrated automated thrombin generation was employed to assess the effect of Andexanet alfa on the coagulant potential of DOAC-treated plasma and whole blood. The study examined anticoagulant inhibition pathways involving tissue factor pathway inhibitor (TFPI), antithrombin, and endothelial cell components. Treatment of control plasmas with rivaroxaban, apixaban, or edoxaban resulted in an impaired thrombin generation, exemplified by a prolonged lag time and reduced thrombin peak height. Andexanet alfa over-converted this anticoagulant activity into a procoagulant effect. Plasma treatment with Andexanet alfa similarly increased thrombin generation in the absence of DOACs, even at 8 nM far below the therapeutic dose. The enhancement was abrogated in the absence or by blocking of TFPI. The Andexanet alfa effect was enhanced in the presence of heparin, thereby reversing the antithrombin protection. In the presence of endothelial cells, Andexanet alfa stimulated coagulation via TFPI and heparin inhibition. Andexanet alfa overconverts the anticoagulant effect of rivaroxaban, apixaban, and edoxaban to achieve a hypercoagulable plasma state. The action mechanism involves TFPI inhibition and neutralization of antithrombin-heparin complexes. This may account for the incidence of thrombosis observed in patients treated with Andexanet alfa.

Autor:innen und Institutionen

  • Department of Clinical Studies, Synapse Research Institute, Maastricht, The Netherlands.
  • Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
  • Department of Anesthesiology, Ziekenhuis Oost Limburg, Genk, Belgium.
  • Department of Anesthesiology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Department of Antidotes, Mithridate BV, Genk, Belgium.

Förderung

  • China Scholarship Council

Zitieren

APA

Hoornstra, I. M. S., Zhao, J., Middelveld, H., Sun, S., Schönichen, C., Heemskerk, J. W. M., Stragier, H., Heylen, R., de Laat, B., & Roest, M. (2025). Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa. Blood Vessels, Thrombosis & Hemostasis, 2(4), 100100. https://doi.org/10.1016/j.bvth.2025.100100

Vancouver

Hoornstra IMS, Zhao J, Middelveld H, Sun S, Schönichen C, Heemskerk JWM, et al. Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa. Blood Vessels, Thrombosis & Hemostasis. 2025;2(4):100100. doi:10.1016/j.bvth.2025.100100

BibTeX
@article{Hoornstra2025,
  author = {Hoornstra, Ischa M S and Zhao, Junxiong and Middelveld, Harmen and Sun, Siyu and Schönichen, Claudia and Heemskerk, Johan W M and Stragier, Hendrik and Heylen, René and de Laat, Bas and Roest, Mark},
  title = {Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2025},
  volume = {2},
  number = {4},
  pages = {100100},
  doi = {10.1016/j.bvth.2025.100100}
}
Kostenlos starten →